EGFR fusions as novel therapeutic targets in lung cancer

Cancer Discovery

Volumn 6, Issue 6, 2016, Pages 601-611

  Konduri, Kartik ^a,b   Gallant, Jean Nicolas ^c   Chae, Young Kwang ^d,e   Giles, Francis J ^d,e   Gitlitz, Barbara J ^f,g   Gowen, Kyle ^h   Ichihara, Eiki ⁱ   Owonikoko, Taofeek K ^j,k   Peddareddigari, Vijay ^l,m   Ramalingam, Suresh S ^j,k   Reddy, Satyanarayan K ^j,k   Eaby Sandy, Beth ^l   Vavalà, Tiziana ^g,n   Whiteley, Andrew ^a   Chen, Heidi ⁱ   Yan, Yingjun ⁱ   Sheehan, Jonathan H ^c   Meiler, Jens ^c,i   Morosini, Deborah ^h   Ross, Jeffrey S ^h,o   Stephens, Philip J ^h   Miller, Vincent A ^h   Ali, Siraj M ^h   Lovly, Christine M ^c,g,i,p   more..

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Northwestern Medicine Developmental Therapeutics Institute ^*  (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Addario Lung Cancer Medical Institute   (United States)

^h FOUNDATION MEDICINE   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k EMORY UNIVERSITY   (United States)

^l HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^m JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o ALBANY MEDICAL COLLEGE   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; INTERLEUKIN 3; OSIMERTINIB; PEMETREXED; RAD51 PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; CANCER LOCALIZATION; CARBOXY TERMINAL SEQUENCE; CELL COUNTING; CELL VIABILITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE FUSION; GENOTYPE; HUMAN; HUMAN TISSUE; IC50; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE BIOPSY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMISTRY; EXON; GENE LOCUS; GENETICS; HIGH THROUGHPUT SEQUENCING; INTRON; LUNG NEOPLASMS; METASTASIS; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PROTEIN CONFORMATION; TUMOR CELL LINE; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; EXONS; FEMALE; GENETIC LOCI; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTRONS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; RAD51 RECOMBINASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 85011990388     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0075     Document Type: Article

References (30)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, etal. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
4. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, etal. Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
6. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. P hase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
7. Gallant J-N, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, etal. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov 2015;5:1155-63.
8. Baik CS, Wu D, Smith C, Martins RG, Pritchard CC. Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication. J Thorac Oncol 2015;10:e97-9.
9. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
11. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988;85:9312-6.
12. Pruss RM, Herschman HR. Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc Natl Acad Sci U S A 1977;74:3918-21.
13. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
14. Chung BM, Dimri M, George M, Reddi AL, Chen G, Band V, etal. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 2009;28:1821-32.
15. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-49.
16. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13: 772-87.
17. Conway AB, Lynch TW, Zhang Y, Fortin GS, Fung CW, Symington LS, etal. Crystal structure of a Rad51 fi lament. Nat Struct Mol Biol 2004;11:791-6.
18. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.
19. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:1-10.
20. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of gliomaversus lung cancer- specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012;2:458-71.
21. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31.
22. Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013; 14: 1326-36.
23. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013; 73: 6770-9.
24. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, etal. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
25. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, etal. Glioblastoma-derived epidermal growth factor receptor carboxyl- terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 2011;71:7587-96.
26. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, etal. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20.
27. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, etal. Identifi cation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
28. Rumora AE, Steere AN, Ramsey JE, Knapp AM, Ballif BA, Kelm RJ. Isolation and characterization of the core single-stranded DNA- binding domain of purine-rich element binding protein B (Pur β). Biochem Biophys Res Commun 2010;400:340-5.
29. Eswar N, Eramian D, Webb B, Shen M-Y, Sali A. Protein structure modeling with MODELLER. Methods Mol Biol 2008;426:145-59.
30. Simons KT, Kooperberg C, Huang E, Baker D. Assembly of protein tertiary structures from fragments with similar local sequences using simulated annealing and Bayesian scoring functions. J Mol Biol 1997;268:209-25.